S Zhong1, X Yan2, Y Wu3, X Zhang1, L Chen4, J Tang5, J Zhao1. 1. Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing, China. 2. Institute of Laboratory Medicine, Jinling Hospital of Nanjing University, Nanjing, China. 3. Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 4. Departments of Oncology, Xuzhou Medical College, Xuzhou, China. 5. Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing, China.
Abstract
BACKGROUND: Previous studies concerning the association between body mass index (BMI) and mortality in prostate cancer yielded mixed results. We investigated the association by performing a meta-analysis of all available studies. METHODS: Relevant studies were identified by searching PubMed and EMBASE to August 2015. We calculated the summary hazard ratio (HR) and 95% confidence interval (CI) using random-effects models. We estimated combined HRs associated with defined increments of BMI, using random-effects meta-analysis and dose-response meta-regression models. RESULTS: Thirty-seven cohort studies and one case-control study involving 27 38 000 patients of prostate cancer were selected for meta-analysis. The summary results indicated higher prediagnosis BMI but not postdiagnosis BMI was associated with increased risk of death from prostate cancer. An increment of every 5 kg/m(2) in prediagnosis BMI was associated with a 15% higher prostate cancer-specific mortality (HR=1.15, 95% CI: 1.07-1.23, P<0.01). Prediagnosis or postdiagnosis BMI showed no effect on all-cause mortality in prostate cancer patients. CONCLUSIONS: In conclusion, higher prediagnosis BMI is associated with a higher risk of death from prostate cancer. Considering the significant heterogeneity among included studies, these findings require confirmation in future studies.
BACKGROUND: Previous studies concerning the association between body mass index (BMI) and mortality in prostate cancer yielded mixed results. We investigated the association by performing a meta-analysis of all available studies. METHODS: Relevant studies were identified by searching PubMed and EMBASE to August 2015. We calculated the summary hazard ratio (HR) and 95% confidence interval (CI) using random-effects models. We estimated combined HRs associated with defined increments of BMI, using random-effects meta-analysis and dose-response meta-regression models. RESULTS: Thirty-seven cohort studies and one case-control study involving 27 38 000 patients of prostate cancer were selected for meta-analysis. The summary results indicated higher prediagnosis BMI but not postdiagnosis BMI was associated with increased risk of death from prostate cancer. An increment of every 5 kg/m(2) in prediagnosis BMI was associated with a 15% higher prostate cancer-specific mortality (HR=1.15, 95% CI: 1.07-1.23, P<0.01). Prediagnosis or postdiagnosis BMI showed no effect on all-cause mortality in prostate cancerpatients. CONCLUSIONS: In conclusion, higher prediagnosis BMI is associated with a higher risk of death from prostate cancer. Considering the significant heterogeneity among included studies, these findings require confirmation in future studies.
Authors: S M Gapstur; P H Gann; L A Colangelo; R Barron-Simpson; P Kopp; A Dyer; K Liu Journal: Cancer Causes Control Date: 2001-10 Impact factor: 2.506
Authors: Henrik Møller; Nina Roswall; Mieke Van Hemelrijck; Signe Benzon Larsen; Jack Cuzick; Lars Holmberg; Kim Overvad; Anne Tjønneland Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Julie K Bassett; Gianluca Severi; Laura Baglietto; Robert J MacInnis; Hoa N Hoang; John L Hopper; Dallas R English; Graham G Giles Journal: Int J Cancer Date: 2012-02-28 Impact factor: 7.396
Authors: Christel Häggström; Tanja Stocks; David Ulmert; Tone Bjørge; Hanno Ulmer; Göran Hallmans; Jonas Manjer; Anders Engeland; Gabriele Nagel; Martin Almqvist; Randi Selmer; Hans Concin; Steinar Tretli; Håkan Jonsson; Pär Stattin Journal: Cancer Date: 2012-10-22 Impact factor: 6.860
Authors: Rachel Huxley; A Ansary-Mohaddam; R Huxley; F Barzi; T H Lam; K Jamrozik; T Ohkubo; X Fang; H J Sun; M Woodward; D F Gu; A Rodgers; Y Imai; W H Pan; I Suh; H J Sun; H Ueshima Journal: Asian Pac J Cancer Prev Date: 2007 Apr-Jun
Authors: Jesco Pfitzenmaier; Maria Pritsch; Axel Haferkamp; Hildegard Jakobi; Frederik Fritsch; Christian Gilfrich; Nenad Djakovic; Stephan Buse; Sascha Pahernik; Markus Hohenfellner Journal: BJU Int Date: 2008-10-24 Impact factor: 5.588
Authors: Jeong Min Park; Jung Soo Nam; Woong Na; Jong Jin Oh; Sangchul Lee; Sung Kyu Hong; Seok-Soo Byun; Sang Eun Lee Journal: Korean J Urol Date: 2012-11-14
Authors: Scott P Kelly; Hannah Lennon; Matthew Sperrin; Charles Matthews; Neal D Freedman; Demetrius Albanes; Michael F Leitzmann; Andrew G Renehan; Michael B Cook Journal: Int J Epidemiol Date: 2019-04-01 Impact factor: 7.196
Authors: Cindy H Chau; Cathee Till; Douglas K Price; Phyllis J Goodman; Marian L Neuhouser; Michael N Pollak; Ian M Thompson; William D Figg Journal: Endocr Relat Cancer Date: 2022-01-20 Impact factor: 5.678
Authors: Scott P Kelly; Barry I Graubard; Gabriella Andreotti; Naji Younes; Sean D Cleary; Michael B Cook Journal: J Natl Cancer Inst Date: 2016-10-20 Impact factor: 13.506